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Introduction: Paraneoplastic Cushing’s syndrome (CushingPS) in 
small-cell lung cancer is rare but severe.
Methods: We studied 383 patients with small-cell lung cancer 
diagnosed between 1998 and 2012. Among them, 23 patients had 
CushingPS, 56 had other paraneoplastic syndrome (OtherPS), and 
304 had no paraneoplastic syndrome (NoPS).
Results: After comparison of the three groups, we observed that 
CushingPS patients had more extensive disease: 82.6% versus 
67.8% versus 53.3% (p = 0.005), respectively, with more than two 
metastatic sites: 63.2% versus 15.8% and 24.1% (p ≤ 0.001), a higher 
World Health Organization performance status (2–4): 73.9% versus 
57.1% versus 43.7% (p = 0.006), greater weight loss (≥10%): 47.8% 
versus 33.9% versus 16.4% (p ≤ 0.001), reduced objective response 
to  first-line treatment: 47.6% versus 74.1% versus 71.1% (p = 0.04), 
and poorer sensitivity to first-line treatment: 19% versus 38.9% ver-
sus 48.6% (p = 0.01). NoPS patients, with World Health Organization 
performance status of 3–4, had extensive disease at diagnosis, with 
response, sensitivity to first-line treatment, and survival similar to the 
CushingPS group. At relapse, the CushingPS group had no objec-
tive response to second-line treatment versus 25% versus 42.8% in 
OtherPS and NoPS groups, respectively (p = 0.005). The median sur-
vival of CushingPS patients was 6.6 months versus 9.2 months for 
OtherPS and 13.1 months for NoPS patients (p ≤ 0.001). CushingPS 
is a prognostic factor of death (hazard ratio, 2.31; p ≤ 0.001).
Conclusion: CushingPS is the worst form of the paraneoplastic 
syndromes with particularly extensive tumors. Reduced objective 
response and sensitivity to first-line treatment and no response to 
second-line treatment suggest starting palliative care early at first line 
and exclusively at relapse.
Key Words: Paraneoplastic Cushing’s syndrome, Small-cell lung 
cancer, Survival.
(J Thorac Oncol. 2014;9: 497–505)
Among lung cancers, the proportion of small-cell lung can-cers (SCLC) has decreased over the last 30 years,1–5 falling 
from 17.26% to 12.95% between 1986 and 2002 in the United 
States.2 In our institution, it has dropped from 22.5% of all lung 
cancers in 1982 to 10% in 2011. Changes in smoking habits 
may explain this evolution. SCLC is notorious because of its 
early metastatic spread and its initial but transient sensitivity to 
chemotherapy.6 The standard first-line treatment is a platinum–
etoposide combination, with radiotherapy for intrathoracic 
forms. The survival rate at 5 years remains low at approxi-
mately 10% for limited forms, with only modest improvement 
over the last 30 years.2,3,7 Prognostic factors that strongly affect 
survival are the initial extent of the tumor,2,3,7 the World Health 
Organization performance status (WHO-PS), sensitivity to 
first-line chemotherapy,7–9 and the presence, or not, of a para-
neoplastic syndrome, particularly Cushing’s syndrome.7,10,11 
Paraneoplastic syndromes are present in 20% to 40% of 
cases.4,12,13 The syndrome of inappropriate antidiuretic hormone 
secretion (SIADH) is the principal one, whereas Cushing’s syn-
drome is present in 1% to 5.5% of cases.11,14–16 Cushing’s syn-
drome is characterized mainly by the inappropriate secretion of 
adreno corticotropic hormone (ACTH), responsible for clinical 
and biological hypercorticism making the SCLC particularly 
severe.10–12,15–17 Other paraneoplastic syndromes are mostly neu-
rological (mainly Lambert–Eaton myasthenia).
In this 14-year retrospective study, we analyzed the 
impact of paraneoplastic Cushing’s syndrome (CushingPS) 
in SCLC in terms of presentation, response to treatment, and 
survival, compared with other SCLC patients. We attempt to 
suggest the treatment strategy to be adopted at the different 
stages of the disease.
PATIENTS AND METHODS
Population
We registered all patients with SCLC, confirmed by 
cytology or histology, presenting at Grenoble University 
Hospital between January 1998 and June 2012.
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Data Collected
We recorded the patient’s age, sex, tobacco consump-
tion, pack-years, occupational exposure, other history of can-
cer, changes in weight, WHO-PS, and Charlson comorbidity 
score.18 We collected their medical characteristics at diagnosis 
including stage (Union for International Cancer Control classi-
fication 1998, 2003, 2007), histology (pure or composite SCLC 
according to the World Health Organization Systematized 
Nomenclature of Medicine classification),19 and whether the 
disease was limited (LD) or extensive (ED). For patients with 
an ED, the tumor bulk was accounted for by dividing the 
patients into those with ≤ 2 organs affected and those with > 2 
organs affected by tumor metastasis. Patients who had a para-
neoplastic syndrome at SCLC diagnosis, and those who devel-
oped one in the course of their disease, were divided into two 
categories: paraneoplastic Cushing's syndrome (CushingPS) 
and other paraneoplastic syndrome (OtherPS), and compared 
to those without paraneoplastic syndrome (NoPS).
Cushing’s syndrome was defined as an excess of corti-
costeroid production with or without clinical signs. At least 
two of the following criteria were required: elevated plasma 
cortisol level (>550 nmol/liter), persistent spontaneous hypo-
kalemia (potassium level <3.2 mmol/liter), hyperglycemia 
(>5.8 mmol/liter) without prior history of diabetes, elevated 
plasma ACTH level (>15 pmol/liter), and 24-hour urinary cor-
tisol level more than 300 nmol/liter.
The details of the first two lines of treatment were 
collected. For patients treated with chemotherapy, tumor 
responses were graded as complete response, partial response, 
stable disease, or progressive disease, using the Response 
Evaluation Criteria in Solid Tumours criteria.20 An objective 
response rate (ORR) was considered complete response + par-
tial response. Sensitive patients were those with an objective 
response 3 months after completing their first-line chemother-
apy. Resistant patients were those with an objective response 
lasting less than 3 months. Refractory patients had no objec-
tive response to their first-line chemotherapy.4,7,8
The first relapse was described in terms of date, sites, 
number of evolving sites (≤2 or >2) WHO-PS, and treatments.
Survival was measured from the start of the first treat-
ment. For patients in palliative care, this is the date of the 
multidisciplinary decision to initiate palliative care. Last 
 follow-up or death and vital status at the last day of the study 
(date point) were recorded, as well as causes of death. No 
patient was lost to follow-up.
Statistical Analysis
Data are expressed as n (%) for qualitative variables and 
mean ± SD and median (first–third quartile) for quantitative 
variables. Standard survival curves were established using the 
method of Kaplan–Meyer and compared using the log-rank 
test. To assess the impact of Cushing’s syndrome on outcomes, 
we first computed a logistic regression with susceptibility to the 
first-line chemotherapy as the outcome variable and introducing 
Cushing’s syndrome at diagnosis. Then, to assess the impact of 
Cushing’s syndrome on prognosis, we performed a Cox regres-
sion and introduced Cushing’s syndrome as a time-dependent 
covariate adjusted on other prognostic factors. Proportionality 
assumptions of the prognostic factors were tested using graphi-
cal methods and taken into account if needed. Variables meet-
ing the p value of 0.20 criteria in the univariate analysis were 
proposed to a selection procedure and were maintained in the 
multivariate model when the p value remained less than 5%. 
Age was not proposed because it is taken into account in the 
Charlson score. The stage and the associated treatments were 
not included because they are highly correlated with the dis-
ease form. All tests were two-sided and a p value of less than 
0.05 was considered statistically significant. Mean survival 
was compared using a Kruskal–Wallis test. Statistical analyses 
were performed using SAS 9.13 (Cary, NC).
RESULTS
During the studied period, 407 SCLC cases were identi-
fied. Among them:
- Three hundred four patients had no paraneoplastic syn-
drome (NoPS).
- Twenty-three patients had Cushing’s syndrome 
(CushingPS), 15 at diagnosis and eight at first relapse.
- Fifty-six patients had other forms of paraneoplastic syn-
drome (OtherPS) including 46 with SIADH (42 at diag-
nosis and four at relapse), four with neuromuscular (three 
with Lambert–Eaton myasthenia and one case of myeli-
tis), three with hypercalcemia (without bone metastases), 
two with osteoarticular, and one with disseminated intra-
vascular coagulation.
- Twenty-four patients (5.9%) with no information about 
paraneoplastic syndrome were excluded.
Thus, this study concerned 383 patients.
Patients with SIADH formed a subgroup of OtherPS. 
To place the CushingPS group on a scale of severity, we 
compared them with a subgroup of NoPS patients having a 
WHO-PS of 3–4 (38 of 304).
Characteristics of Patients with 
Cushing’s Syndrome
These patients, mostly with ED (19 of 23 or 82.6%) 
with more than two metastatic sites (12 of 19 or 63.2%), 
were in poor general condition with WHO-PS 2 to 4 (17 of 
23 or 74%) (Tables 1–3 and Supplementary Tables 1–4, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A533). Nearly half of them had lost more than or equal to 
10% of their baseline weight (11 of 23, 47.8%). More than 
half presented cachexia, edema, hypertension, and/or muscle 
weakness. Hyperglycemia and hypokalemia were practically 
continual (21 of 23 or 91.3%), whereas metabolic alkalosis 
and lymphopenia affected the majority of them (69.6% and 
65.2%, respectively), the latter contributing to their immu-
nosuppression. Plasma cortisol levels (median, 1934.5 nmol/
liter), ACTH (median, 59.6 pmol/liter), and cortisoluria over 
24 hours (median, 3199.5 nmol/24 hr) supported the diagnosis. 
One patient, with a very characteristic clinical profile, was kept 
in the study, although she died before the hormone assays.
Cushing’s syndrome progression was marked by almost 
constant infectious complications (20 of 23 or 86.9%), 
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TABLE 1.  Patient Characteristics
All Patients
No Paraneoplastic 
Syndrome
Type of Paraneoplastic Syndrome
Paraneoplastic 
Cushing’s Syndrome
Other Paraneoplastic 
Syndrome
Syndrome of Inappropriate 
Secretion of Antidiuretic 
Hormone Alone
n = 383 (%) n = 304 (%) n = 23 (%) n = 56 (%) n = 46 (%)
Sex
  Female 85 (22.2) 69 (22.7) 7 (30.4) 9 (16.1) 7 (15.2)
  Male 298 (77.8) 235 (77.3) 16 (69.5) 47 (83.9) 39 (84.8)
Age
  Mean (SD) 63.9 (10.6) 63.8 (10.5) 60.7 (13.8) 66.1 (9.7) 65.9 (10)
  Median (q1; q3) 64 (56; 72) 64 (56; 71) 62 (51; 71) 67 (56–76) 67 (55; 76)
  <60 136 (35.5) 107 (35.2) 10 (43.5) 19 (33.9) 16 (34.8)
  ≥60 247 (64.5) 197 (64.8) 13 (56.5) 37 (66.1) 30 (65.2)
  Minimum–maximum 29–88 34–88 29–84 48–83 48–83
Professional exposure
  Asbestos 62 (17.4) 46 (16.3) 3 (13) 13 (23.2) 11 (23.9)
  Other 70 (19.7) 56 (19.9) 5 (21.7) 9 (16.1) 8 (17.4)
Tobacco
  Smokers 349 (91.1) 278 (91.4) 21 (91.3) 50 (89.3) 42 (91.3)
  Nonsmokers 11 (2.9) 7 (2.3) 2 (8.7) 2 (3.6) 1 (2.2)
  Unknown status 23 (6) 19 (6.2) 4 (7.1) 3 (6.5)
Pack-years
  Mean (SD) 46.9 (26.6) 47.4 (26.1) 39.4 (19.1) 47.6 (31.3) 49.3 (32.1)
  Median (q1; q3) 40 (30; 60) 40 (30; 60) 40 (30; 50) 45 (25; 60) 42.5 (25; 60)
Weight gain
  +10 kg 1 (0.3) 1 (4.3)
Weight: loss
  <10% 287 (74.9) 242 (79.6) 11 (47.8) 34 (60.7) 31 (67.4)
  ≥10% 80 (20.9) 50 (16.4) 11 (47.8) 19 (33.9) 13 (28.3)
  ND 15 (3.9) 12 (3.9) 3 (5.3) 2 (4.3)
Charlson score
  <4 179 (46.7) 145 (47.7) 11 (47.8) 23 (41.1) 19 (41.3)
  ≥4 204 (53.3) 159 (52.3) 12 (52.2) 33 (58.9) 27 (58.7)
Cancer history
  Yes 63 (16.4) 45 (14.8) 4 (17.4) 14 (26) 10 (21.7)
World Health Organization performance status
  0–1 200 (52.4) 170 (56.1) 6 (26.1) 24 (42.8) 21 (45.7)
  2 126 (33) 95 (31.4) 12 (52.2) 19 (33.9) 14 (30.4)
  3–4 56 (14.7) 38 (12.5) 5 (21.7) 13 (23.2) 11 (23.9)
  ND 1 (0.3) 1 (0.3)
Stage
  1–3A 79 (20.6) 69 (22.9) 2 (8.7) 8 (14.3) 4 (8.7)
  3B, 4 301 (78.6) 232 (77.1) 21 (91.3) 48 (85.7) 42 (91.3)
  Missing 3 (0.8) 3 (1.0)
Disease extension
  Limited disease 163 (42.6) 141 (46.4) 4 (17.4) 18 (32.4) 12 (26.1)
  ED 219 (57.2) 162 (53.3) 19 (82.6) 38 (67.8) 34 (73.9)
  ND 1 (0.3) 1 (0.3)
ED: metastatic sites at diagnosis
  ≤2 162 (74) 123 (75.9) 7 (36.8) 32 (57.1) 29 (85.3)
  >2 57 (26) 39 (24.1) 12 (63.2) 6 (10.7) 5 (14.7)
Histology
  SCLC classical 346 (90.3) 274 (90.1) 20 (87) 52 (92.8) 43 (93.5)
  SCLC composite 37 (9.7) 30 (9.9) 3 (13) 4 (7.1) 3 (6.5)
ND, not documented; ED, extensive disease; SCLC, small-cell lung cancer.
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TABLE 2.  Treatments: First and Second Lines
All 
Patients
No 
Paraneoplastic 
Syndrome
With Paraneoplastic Syndrome
Paraneoplastic 
Cushing’s 
Syndrome
Other 
Paraneoplastic 
Syndrome
Syndrome of Inappropriate 
Secretion of Antidiuretic 
Hormone Alone
n = 383 n = 304 n = 23 n = 56 n = 46
First-line treatments
  Treatments with  
 chemotherapy
Chemotherapy 369 (96.3) 294 (96.7) 21 (91.3) 54 (96.4) 44 (95.6)
With curative surgery 25 (6.5) 25 (8.2)
With radiotherapy 106 (27.7) 95 (31.2) 3 (13.0) 8 (14.3) 6 (13)
  Treatments without 
 chemotherapy
Surgery alone 1 (0.3) 1 (4.3)
Radiotherapy alone 3 (0.8) 3 (0.1)
Palliative care 10 (2.6) 7 (2.3) 1 (4.3) 2 (3.6) 2 (4.3)
All treatments without 
chemotherapy
14 (3.6) 10 (3.3) 2 (8.7) 2 (3.6) 2 (4.3)
  Chemotherapy response First line 369 294 21 54 44
ORR (CR + PR) 259 (70.2) 209 (71.1) 10 (47.6) 40 (74.1) 32 (72.7)
Stable 34 (9.2) 24 (8.2) 6 (28.6) 4 (7.4) 4 (9.1)
Progression 49 (13.3) 41 (13.9) 1 (4.8) 7 (12.9) 6 (13.6)
NE 21 (5.7) 14 (4.8)) 4 (19) 3 (5.5) 2 (4.5)
ND 6 (1.6) 6 (2)
  Sensitivity to first line Refractory 85 (23) 66 (22.4) 7 (33.3) 12 (22.2) 11 (25)
Resistant 86 (23.3) 63 (21.4) 5 (23.8) 18 (33.3) 14 (31.8)
Sensitive 168 (45.5) 143 (48.6) 4 (19) 21 (38.9) 17 (38.6)
NE 24 (6.5) 16 (5.4) 5 (23.8) 3 (5.5) 2 (4.5)
ND 6 (1.6) 6 (2)
  Relapse 287 227 17 43 36
  World Health Organization 
 performance status 
 (at relapse)
0–1 110 (38.3) 99 (43.6) 2 (11.8) 9 (20.9) 9 (25)
2 92 (32) 72 (31.7) 4 (23.5) 16 (37.2) 15 (41.7)
3–4 68 (23.7) 43 (18.9) 9 (52.9) 16 (37.2) 12 (33.3)
ND 17 (5.9) 13 (5.7) 2 (11.8) 2 (4.6)
  Local recurrence Yes 190 (66.2) 149 (65.6) 10 (58.8) 31 (72.1) 27 (75)
ND 5 (1.7) 3 (1.3) 1 (5.9) 1 (2.3) 1
  Metastatic recurrence Yes 199 (69.3) 154 (67.8) 16 (94.1) 29 (67.4) 23 (63.9)
ND 5 (1.7) 3 (1.3) 1 (5.9) 1 (2.3) 1
  Evolving sites ≤2 234 (81.5) 189 (83.3) 9 (52.9) 36 (83.7) 29 (80.6)
>2 48 (16.7) 35 (15.4) 7 (41.2) 6 (13.9) 6 (16.7)
ND 5 (1.7) 3 (1.3) 1 (5.9) 1 (2.3) 1 (2.8)
Second-line treatments Chemotherapy 208 (72.5) 166 (73.1) 10 (58.8) 32 (74.4) 29 (80.5)
  Chemotherapy: response  
 to second line
ORR (CR + PR) 79 (38) 71 (42.8) 0 8 (25) 8 (27.6)
Stable 35 (16.8) 27 (16.3) 2 (20) 6 (18.7) 4 (13.8)
Progression 85 (40.9) 60 (36.1) 7 (70) 18 (56.2) 17 (58.6)
NE 6 (2.9) 5 (3) 1 (10)
ND 3 (1.4) 3 (1.8)
  Other treatments 2 Radiotherapy 18 17 1
Palliative care 58 (20.2) 42 (18.5) 6 (35.3) 10 (23.2) 7 (19.4)
ND 3 2 1
  Death No 34 (8.9) 27 (8.9) 1 (4.3) 6 (10.7) 4 (8.7)
Yes 349 (91.1) 277 (91.1) 22 (95.7) 50 (89.3) 42 (91.3)
  Causes of death Cancer 310 (88.8) 247 (89.2) 18 (81.8) 45 (90) 38 (90.5)
Iatrogenic 
complications
23 (6.6) 16 (5.8) 2 (9.1) 5 (10) 4 (9.5)
Other 16 (4.6) 14 (5.1) 2 (9.1)
ORR, objective response rate; CR, complete response; PR, partial response; NE, not evaluable; ND, not documented.
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jeopardizing the vital prognosis in nearly half the cases (11 
of 20 or 55%). Fifteen patients (65.2%) had received specific 
treatment for Cushing’s syndrome, but eight untreated patients 
died prematurely (mean survival, 17.5 days); the majority of 
these patients had been diagnosed at relapse (5 of 8). Among 
those responsive to treatment for Cushing’s syndrome, 11 of 
13 (84.6%) had presented the syndrome at diagnosis of SCLC. 
Most patients (21 of 23 or 91.3%) received chemotherapy. The 
ORR was low (10 of 21 or 47.6%). Sensitivity to the  first-line 
chemotherapy was poor (4 responders/21 treated or 19%), 
and no response was obtained on second-line treatment. At 
the time of relapse, 13 of 17 patients (76.4%) had a WHO-PS 
more than or equal to 2, and seven (41%) had more than two 
sites with disease progression. Death, mostly related to tumor 
progression (18 of 22 or 81.8%), was hastened by septic com-
plications still present in almost half the cases (10 of 22 or 
45.5%) at the time of death.
Comparison with Other Groups
There was no difference between the groups in terms 
of sex and age. Almost all patients were heavy smokers 
(>40 pack yr) (Tables 1 and 2 and Supplementary Table 
5, Supplementary Digital Content, http://links.lww.com/
JTO/A533).
Presentation at diagnosis
1. A comparison of the 79 patients with a paraneoplastic 
syndrome with the 304 NoPS patients showed them more 
likely to present factors indicative of poor prognosis 
including weight loss of more than or equal to 10% (38% 
versus 16.4%, p ≤ 0.001), high WHO-PS score 2 to 4 in 
62.0% versus 43.7% (p = 0.004), greater disease diffu-
sion at diagnosis in ED: 72.1% versus 53.3% (p = 0.003), 
and attenuated sensitivity to first-line chemotherapy of 
33.3% versus 48.6% (p = 0.01).
TABLE 3.  Cushing’s Syndrome: Clinical and Biological Signs
Clinical signs na n (%)
Hypertension (23) 13 (56.5)
Edemas (21) 11 (52.4)
Myopathy (20) 11 (55)
Obesity (23) 4 (17.4)
Cachexy (23) 14 (60.9)
Bowel disorder (22) 5 (22.7)
Cutaneous disorder (15) 4 (26.7)
Neurological disorder (17) 3 (17.6)
Heart rate disorder (22) 3 (13.6)
  Complications
   Infection All (23) 20 (86.9)
Of which: serious sepsis (20) 9 (45)
Of which: opportunistic (20) 4 (20)
   Digestive perforation 23 3 (13)
   Cardiac 23 2 (8.7)
  Treatment for Cushing’s
Yes 15 (65.2)
No 8 (34.8)
  Treatment response n = 15
Complete (15) 1 (6.7)
Partial (15) 12 (80)
No response (15) 2 (13.3)
  Death: secondary causes n = 22
Cardiac 2 (9.1)
Infectious 10 (45.5)
Biological signs (normal values), n = no. of tested subjects Mean (SD), median (q1; q3) ↑ High; ↓ low (%); → normal
  Blood cortisol level nmol/liter (150–400), n =22 1934.5 (966.8), 2011 (1129; 2553) ↑ 20 (95.2); → 1 (4.5)
  Cortisoluria nmol/24 hr (38–208), n = 11 3199.5 (2843), 2344 (1377; 6045) ↑ 11 (100)
  ACTH (2–13 pmol/liter), n = 13 59.6 (64.8), 46 (13.3; 73.8) ↑10 (77); ↓ 1; → 2
  Glycemia mmol/liter (3.8–5.8), n = 23 10.4 (6.8), 7.9 (7.2; 10.4) ↑ 22 (95.6); → 1
  Kalemia mmol/liter (3.5–5.0), n = 23 2.6 (0.6), 2.6 (2.2; 2.8) ↓22 (95.6); → 1
  Bicarbonates mmol/liter (24–32), n = 23 34.4 (6.2), 35 (29; 39) ↑ 17 (73.9); → 6
  Lymphocytes G/liter (0.8–3.6), n = 23 1 (1.4), 0.5 (0.4; 1) ↓ 15 (65.2); → 7; ↑ 1
aNo. of patients tested or concerned.
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2. A comparison of the CushingPS with OtherPS and NoPS 
patients confirmed the accumulation of factors linked to 
severity, with the most significant differences concern-
ing weight loss of more than or equal to 10%: 47.8% 
versus 33.9% versus 16.4% (p ≤ 0.001), WHO-PS score 
2 to 4: 73.9% versus 57.1% versus 43.7% (p = 0.006), 
more ED: 82.6% versus 67.8% versus 53.3% (p = 0.005), 
with more than two metastatic sites: 63.2% versus 15.8% 
and 24.1% (p ≤ 0.001), lower objective response to the 
first-line chemotherapy: 47.6% versus 74.1% and 71.1% 
(p = 0.04), and a reduced sensitivity to chemotherapy: 
19% versus 38.9% versus 48.6% (p = 0.007).
3. Comparison of the CushingPS group with the “SIADH 
only” subgroup confirmed that this is the most severely 
affected group in terms of major tumor extension (>2 
metastatic sites) with 63.2% versus 14.7% (p ≤ 0.001).
4. Comparison of the CushingPS group with the subgroup 
of patients “NoSP and WHO-PS 3–4” (Supplementary 
Table 5, Supplementary Digital Content, http://links.
lww.com/JTO/A533) indicated that they are equivalent 
in terms of weight loss, extent of tumor diffusion, objec-
tive response, and sensitivity to first-line chemotherapy. 
The CushingPS group was always recognizable by par-
ticularly diffuse forms at diagnosis (>2 metastatic sites) 
with 63.2% versus 31.2% (p = 0.03).
At relapse
1. The comparison of the CushingPS group and NoPS 
group showed an increase in factors of severity in terms 
of WHO-PS score 2–4: 76.5% versus 50.6% (p = 0.01).
2. The comparison of the CushingPS group with OtherPS 
and NoPS groups showed more tumor diffusion (>2 
evolving sites): 41.2% versus 13.9% versus 15.4% 
(p ≤ 0.001) and lack of response to the second-line che-
motherapy: 0% versus 25% versus 42.8% (p = 0.005).
Survival
At the last follow-up point (March 11, 2013), 349 
patients (91.1%) had died. The median follow-up of the 34 
patients still alive was 41.9 months. The median survival 
for the entire group was 11.8 months (Table 4, Fig. 1, and 
Supplementary Table 6, Supplementary Digital Content, 
http://links.lww.com/JTO/A533).
The median survival for NoPS was 13.1 versus 8.1 
months for those with a paraneoplastic syndrome (p ≤ 0.001). 
The CushingPS group had poorer survival compared with 
OtherPS group (6.6 versus 9.2 mo, p = 0.02) and SIADH only 
patients (6.6 versus 8.5 mo, p = 0.04). Their survival was com-
parable to that of patients “NoPS with WHO-PS 3–4,” median 
6.6 months versus 3.3 months (p = 0.69). Patients presenting 
Cushing’s syndrome at SCLC diagnosis had a median survival 
of 4.8 months.
When Cushing’s syndrome was diagnosed at relapse, 
the survival of these patients (all now deceased) was par-
ticularly poor with death within an average of 27.3 days 
of this diagnosis. For patients deceased (22 of 23), those 
with Cushing’s syndrome controlled by treatment survived 
an average of 298 days (from the diagnosis of cancer) and 
243 days (from diagnosis of Cushing’s syndrome) compared 
with 110 and 18 days, respectively, for those for whom 
Cushing’s syndrome was untreated or uncontrolled (both 
Kruskal–Wallis p ≤ 0.001) and whom had mainly been diag-
nosed at relapse.
Multivariate Analysis
1. The logistic regression (Table 5) looking at the impact of 
Cushing’s syndrome on the sensitivity to first-line che-
motherapy was done with the subgroup of 15 patients 
presenting Cushing’s syndrome at SCLC diagnosis. Of 
these, 14 of 15 patients (93.3%) had WHO-PS 2 to 4, 
an ED, and received chemotherapy; seven of 14 (50%) 
achieved an ORR and two of 14 (14.3%) were sensitive 
(Supplementary Table 4, Supplementary Digital Content, 
http://links.lww.com/JTO/A533). Predictors of negative 
response to first-line chemotherapy were a WHO-PS 3 
and 4, odds ratio (OR) 3.25 (p = 0.02); extended disease, 
OR 4.3 (p ≤ 0.001); and composite histology, OR 4.86 
(p = 0.001).
2. The multivariate Cox model (Table 5) looked at the 
impact of Cushing’s syndrome on the risk of death and 
considered the whole group (23 patients). The risk fac-
tors for death were Cushing’s syndrome: hazard ratio 
(HR), 2.31 (p ≤ 0.001); Charlson score more than or 
equal to 4: HR, 1.71 (p ≤ 0.001); WHO-PS more than or 
equal to 2: for WHO-PS = 2: HR, 1.44 (p = 0.004) and 
WHO-PS 3–4: HR, 2.65 (p ≤ 0.001); and ED: HR, 3.05 
(p ≤ 0.001). A classical SCLC histology after 119 days 
was a protective factor: HR, 0.52 (p = 0.001).
DISCUSSION
CushingPS in a context of lung cancer is seen in cases 
of neuroendocrine tumors whose malignancy ranges from that 
of carcinoid tumors to SCLC, the most severe form.10,14,21–23 
In the 1990s, historical case studies and small cohort stud-
ies permitted us to highlight the extreme severity of this syn-
drome when associated with SCLC, showing the dominance 
of ED, with infectious complications making perilous any 
administration of chemotherapy, and the short survival of pati
ents.11,12,15–17,24–26 Our group of patients was consistent with the 
initial descriptions. Detailed analysis from patient presenta-
tion to diagnosis allowed us to observe the particularly dif-
fuse spread of the disease, defined as metastasis to at least two 
other organs. The magnitude of weight loss, alteration of per-
formance status, and poor response to first-line chemotherapy 
surpassed all other groups and made this the most severe of all 
paraneoplastic syndromes. Finally, the profile of these patients 
at presentation and the disease progression was similar to that 
of patients with poor performance status3,4 but without para-
neoplastic syndrome.
CushingPS and SCLC reinforce each other’s deleteri-
ous effects. The immunodepression that accompanies cancer-
ous states is amplified by that induced by the hypercorticism, 
leading to severe infectious complications, usually opportu-
nistic. Metabolic disorders (hypokalemia, metabolic alkalosis, 
diabetes) with their own clinical consequences considerably 
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aggravate the worsening of the general state of health brought 
about by the rapid development of SCLC.
The occurrence of a paraneoplastic syndrome is directly 
linked to the tumor bulk. In our cohort, 72% of patients pre-
senting a paraneoplastic syndrome of whatever type had ED at 
diagnosis. Our study suggests that in such cases, Cushing’s syn-
drome is often found when the tumor bulk is particularly large 
and thus heterogeneous, with three or more organs affected by 
metastasis. This heterogeneity could explain the increased risk 
of the emergence of cellular clones with abnormal hormonal 
activity. When Cushing’s syndrome was diagnosed, 22 of 23 
patients (95.6%) had ED. This observation is in line with the 
study by Shepherd et al.12 and individual case reports.11,17,24
If the diagnosis of Cushing’s syndrome when it occurs 
alone is a complex diagnostic challenge,22,27 the presence of 
SCLC, with its noisy symptoms, can readily help to associ-
ate the two pathologies. Simple biological parameters such as 
hypokalemia and/or hyperglycemia and/or lymphopenia and 
metabolic alkalosis, accessible from the initial assessment of 
known SCLC, can suggest CushingPS and the need to assay 
plasma cortisol at 8 and 24 hours cortisoluria to confirm the 
diagnosis, even when Cushing’s syndrome on its own would 
have little clinical expression.
Many authors stress the need to control the hypercorticism 
by specific treatment before chemotherapy to prevent infectious 
complications that are facilitated by  glucocorticoid-induced 
immunosuppression and  chemotherapy-induced agranulo-
cytosis despite the use of leukocyte growth factors.11,12,15,17,26 
Some authors advocate systematic antifungal treatment15 
in view of the risk of the infectious complications that are 
TABLE 4.  Survival
n p
Median (mo) (95% 
Confidence Interval)
Alive at 1 
yr, n (%)
Alive at 2 
yr, n (%)
Alive at 5 
yr, n (%)
All patients 383 11.8 (10.6–13.1) 191 (49) 92 (23) 41 (8)
Limited disease 163 <103 20.7 (17.2–25.4) 122 (75) 74 (44) 32 (16)
Extensive disease 219 8.3 (7.6–8.9) 69 (31) 18 (6) 9 (1)
No PS 304 0.0002 13.1 (11.2–14.9) 164 (54) 80 (25) 33 (8)
All PS 79 8.1 (6.7–11.1) 27 (33) 12 (13) 8 (7)
Cushing’ PS (at diagnosis) 15 4.8 (0.3–12.1) 5 (33) 0 0
Cushing’ PS (all patients) 23 0.02 6.6 (3.2–11.4) 6 (24) 0 0
Other PS 56 9.2 (7.0–11.9) 21 (37) 21 (18) 7 (9)
Syndrome of inappropriate secretion of 
antidiuretic hormone alone
46 0.04a 8.5 (6.8–11.9) 16 (34) 9 (18) 5 (6)
No PS and World Health Organization 
performance status 3–4
38 0.69b 3.3 (1.5–7.0) 8 (21) 1 (2.6) 0
aCushing’ PS (all patients) vs syndrome of inappropriate secretion of antidiuretic hormone alone.
bCushing’ PS (all patients) vs no PS and World Health Organization performance status 3–4.
PS, paraneoplastic syndrome.
FIGURE 1.  Survival curve of the three groups: Cushing: 
Cushing’s paraneoplastic syndrome, n = 23; other PS, other 
paraneoplastic syndrome, n = 56; without PS: no paraneoplas-
tic syndrome, n = 304 (log-rank p < 0.0001). PS, paraneoplas-
tic syndrome.
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correlated with elevated plasma cortisol levels.15,25 In terms 
of the antitumor treatment, the objective response to first-
line chemotherapy was diminished. This finding is in line 
with small series studies12,16,26 and is stressed in individual 
case reports.11,17,24 In our univariate analysis, we showed that 
a reduced ORR was specific to Cushing’s syndrome patients 
compared with other groups. Furthermore, in univariate anal-
ysis the sensitivity to first-line chemotherapy was poor, com-
pared to when Cushing’s syndrome was absent. It was similar 
to that of WHO-PS 3–4 patients without a paraneoplastic syn-
drome. In multivariate analysis, while Cushing’s syndrome 
itself did not appear as a specifically pejorative factor for sen-
sitivity to first-line chemotherapy, we believe that it is syn-
onymous with high WHO-PS and ED. Nevertheless, it clearly 
seems to be a specific risk factor for death. At relapse, none 
of the 10 CushingPS patients who received second-line che-
motherapy gained any benefit, compared with NoPS patients 
where a 42.8% ORR was obtained (p = 0.006, Fisher’s two-
sided test). This result is explained by the very poor condi-
tion of patients with CushingPS in relapse (high WHO-PS and 
extensive tumor diffusion) and is linked to their poor response 
to the first-line treatment. This is in line with recent reapprais-
als of second-line chemotherapy for SCLC, which highlight 
the poor response at second line of patients who were refrac-
tory or resistant to first-line treatment.7–9 Many studies agree 
that there should be greater emphasis on early palliative care 
in conjunction with antitumor treatments to improve the qual-
ity of life and survival of patients with advanced lung can-
cers.28–32 This is also true for patients with cancers of various 
origins who are no longer receiving antitumor treatment.33 The 
deleterious effect of chemotherapy administered at the end of 
life has already been demonstrated and is particularly useless 
in patients with performance status 3 and 4. Not only does it 
have no positive effect on the disease, but it aggravates the 
discomfort of patients and impedes the administration of affir-
mative palliative action.34,35
Proposals
All these considerations lead us to propose screening 
for CushingPS by cortisolemia at 8 AM and/or assay of cor-
tisoluria more than 24 hours in patients with SCLC or ED 
with unexplained hypokalemia and/or hyperglycemia and/or 
lymphopenia. The earliest possible diagnosis will allow the 
establishment of specific treatment before chemotherapy. In 
cases with a diagnosis of SCLC when Cushing’ syndrome 
is already established, it seems logical to renounce giving 
chemotherapy (temporarily or permanently) to patients with 
uncontrolled cortisolemia, with performance status 3 or 4, 
who already present infectious complications and/or who are 
too old. At relapse, the finding of Cushing’s syndrome must 
shift the focus to palliative care. A second line should only 
be discussed on a case-by-case basis by a multidisciplinary 
review group.
Limitations
In this study, we considered paraneoplastic syndromes 
diagnosed throughout SCLC evolution to define the groups of 
patients. Although this is an unusual method, it allowed us to 
constitute independent groups, where each patient was attrib-
uted to a single group. Our study has the limitation of being 
monocentric; however, this guaranteed consistency in data 
collection and clinical practice. The small number of patients 
with Cushing’s syndrome has forced us to restrict our com-
parisons to the most relevant parameters.
TABLE 5.  Multivariate Analysis
Logistic regression: sensitivity to first-line chemotherapy
Variable Odds ratio 95% CI p
 Cushing’s syndrome at diagnosis: (15 patients) 2.75 0.54–13.99 0.22
 Pack years >40 1.70 1.02–2.83 0.04
 WHO-PS: 2 1.59 0.90–2.81 0.69
 WHO-PS: 3–4 3.25 1.42–7.45 0.02
 Extensive disease 4.33 2.57–7.28 <0.0001
 Composite histology 4.86 1.88–12.57 0.001
Cox multivariate model: risk of deatha
 Variable Hazard ratio 95% CI p
 Time dependent Cushing’s syndrome (23 patients) 2.31 1.47–3.64 0.0003
 Classical SCLC before 120 days 1.15 0.42–3.19 0.79
 Classical SCLC after 119 days 0.52 0.35–0.78 0.001
 Charlson score ≥4 1.71 1.37–2.13 <0.0001
 WHO-PS: 2 1.44 1.12–1.84 0.004
 WHO-PS: 3–4 2.65 1.89–3.72 <0.0001
 Extensive disease 3.05 2.39–3.91 <0.0001
 Chemotherapy: yes 0.20 0.11–0.36 <0.0001
aTime in days.
CI, confidence interval; WHO-PS, World Health Organization performance status; SCLC, small-cell lung cancer.
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CONCLUSION
In SCLC, patients Cushing’s syndrome is the most 
severe form of paraneoplastic syndrome. Its presence is 
related to particularly extensive tumors in patients who have 
poor performance status and excessive weight loss. Their 
objective response to first-line chemotherapy is impaired and 
is nonexistent to second-line chemotherapy, leading us to pro-
pose an early introduction of palliative care accompanying the 
first-line treatment and palliative care only at relapse.
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